•An Innovative biotech poised to establish new standards of care across major solid tumors (NSCLC, colorectal, pancreatic, prostate, SCLC, head and neck, and esophageal cancers, etc), while also advancing therapies for IBD, atopic dermatitis, and other autoimmune diseases.

•Operating in stealth mode with a pipeline of ~10 first-in-class and best-in-class bispecific antibodies and bispecific ADCs.

•Backed by Hillhouse and other leading global investment funds.